These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

836 related articles for article (PubMed ID: 29225057)

  • 1. Comparison of Pathological and Oncologic Outcomes of Favorable Risk Gleason Score 3 + 4 and Low Risk Gleason Score 6 Prostate Cancer: Considerations for Active Surveillance.
    Gearman DJ; Morlacco A; Cheville JC; Rangel LJ; Karnes RJ
    J Urol; 2018 May; 199(5):1188-1195. PubMed ID: 29225057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. National Comprehensive Cancer Network® Favorable Intermediate Risk Prostate Cancer-Is Active Surveillance Appropriate?
    Aghazadeh MA; Frankel J; Belanger M; McLaughlin T; Tortora J; Staff I; Wagner JR
    J Urol; 2018 May; 199(5):1196-1201. PubMed ID: 29288120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Limitations in Predicting Organ Confined Prostate Cancer in Patients with Gleason Pattern 4 on Biopsy: Implications for Active Surveillance.
    Perlis N; Sayyid R; Evans A; Van Der Kwast T; Toi A; Finelli A; Kulkarni G; Hamilton R; Zlotta AR; Trachtenberg J; Ghai S; Fleshner NE
    J Urol; 2017 Jan; 197(1):75-83. PubMed ID: 27457260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subtyping the Risk of Intermediate Risk Prostate Cancer for Active Surveillance Based on Adverse Pathology at Radical Prostatectomy.
    Patel HD; Gupta M; Tosoian JJ; Carter HB; Partin AW; Epstein JI
    J Urol; 2018 Nov; 200(5):1068-1074. PubMed ID: 29673946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Biochemical Recurrence-Free Survival after Radical Prostatectomy Triggered by Grade Reclassification during Active Surveillance and in Men Newly Diagnosed with Similar Grade Disease.
    Diniz CP; Landis P; Carter HB; Epstein JI; Mamawala M
    J Urol; 2017 Sep; 198(3):608-613. PubMed ID: 28347771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathological, oncologic and functional outcomes of radical prostatectomy following active surveillance.
    Satkunasivam R; Kulkarni GS; Zlotta AR; Kalnin R; Trachtenberg J; Fleshner NE; Hamilton RJ; Jewett MA; Finelli A
    J Urol; 2013 Jul; 190(1):91-5. PubMed ID: 23321581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Outcomes after Deferred Radical Prostatectomy in Men Initially Treated with Active Surveillance.
    Godtman RA; Schafferer M; Pihl CG; Stranne J; Hugosson J
    J Urol; 2018 Oct; 200(4):779-785. PubMed ID: 29730198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathological Outcome following Radical Prostatectomy in Men with Prostate Specific Antigen Greater than 10 ng/ml and Histologically Favorable Risk Prostate Cancer.
    Yu J; Kwon YS; Kim S; Han CS; Farber N; Kim J; Byun SS; Kim WJ; Jeon SS; Kim IY
    J Urol; 2016 May; 195(5):1464-1470. PubMed ID: 26608903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of Extraprostatic Extension at Radical Prostatectomy with Pure Gleason Score 3 + 3 = 6 (Grade Group 1) Cancer: Implications for Whether Gleason Score 6 Prostate Cancer Should be Renamed "Not Cancer" and for Selection Criteria for Active Surveillance.
    Hassan O; Han M; Zhou A; Paulk A; Sun Y; Al-Harbi A; Alrajjal A; Baptista Dos Santos F; Epstein JI
    J Urol; 2018 Jun; 199(6):1482-1487. PubMed ID: 29154905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biopsy Core Features are Poor Predictors of Adverse Pathology in Men with Grade Group 1 Prostate Cancer.
    Audenet F; Vertosick EA; Fine SW; Sjoberg DD; Vickers AJ; Reuter VE; Eastham JA; Scardino PT; Touijer KA
    J Urol; 2018 Apr; 199(4):961-968. PubMed ID: 29030317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathological outcomes in men with low risk and very low risk prostate cancer: implications on the practice of active surveillance.
    Tosoian JJ; JohnBull E; Trock BJ; Landis P; Epstein JI; Partin AW; Walsh PC; Carter HB
    J Urol; 2013 Oct; 190(4):1218-22. PubMed ID: 23643603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Older Age Predicts Biopsy and Radical Prostatectomy Grade Reclassification to Aggressive Prostate Cancer in Men on Active Surveillance.
    Druskin SC; Mamawala M; Tosoian JJ; Epstein JI; Pavlovich CP; Carter HB; Trock BJ
    J Urol; 2019 Jan; 201(1):98-104. PubMed ID: 30114397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor Volume on Biopsy of Low Risk Prostate Cancer Managed with Active Surveillance.
    Tosoian JJ; Mamawala M; Patel HD; Alam R; Epstein JI; Ross AE; Carter HB
    J Urol; 2018 Apr; 199(4):954-960. PubMed ID: 29074222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does Time Spent on Active Surveillance Adversely Affect the Pathological and Oncologic Outcomes in Patients Undergoing Delayed Radical Prostatectomy?
    Ahmad AE; Richard PO; Leão R; Hajiha M; Martin LJ; Komisarenko M; Grewal R; Goldberg H; Salem S; Jain K; Oliaei A; Horyn I; Timilshina N; Zlotta A; Hamilton R; Kulkarni G; Fleshner N; Alibhaic SMH; Finelli A
    J Urol; 2020 Sep; 204(3):476-482. PubMed ID: 32259466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
    Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
    J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse Disease Features in Gleason Score 3 + 4 "Favorable Intermediate-Risk" Prostate Cancer: Implications for Active Surveillance.
    Morlacco A; Cheville JC; Rangel LJ; Gearman DJ; Karnes RJ
    Eur Urol; 2017 Sep; 72(3):442-447. PubMed ID: 27574819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selecting Patients with Favorable Risk, Grade Group 2 Prostate Cancer for Active Surveillance-Does Magnetic Resonance Imaging Have a Role?
    Stonier T; Tin AL; Sjoberg DD; Jibara G; Vickers AJ; Fine S; Eastham J
    J Urol; 2021 Apr; 205(4):1063-1068. PubMed ID: 33216696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 17-Gene Genomic Prostate Score as a Predictor of Adverse Pathology in Men on Active Surveillance.
    Kornberg Z; Cooperberg MR; Cowan JE; Chan JM; Shinohara K; Simko JP; Tenggara I; Carroll PR
    J Urol; 2019 Oct; 202(4):702-709. PubMed ID: 31026214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What is the optimal definition of misclassification in patients with very low-risk prostate cancer eligible for active surveillance? Results from a multi-institutional series.
    Gandaglia G; Ploussard G; Isbarn H; Suardi N; De Visschere PJ; Futterer JJ; Ghadjar P; Massard C; Ost P; Sooriakumaran P; Surcel CI; van der Bergh RC; Montorsi F; Ficarra V; Giannarini G; Briganti A;
    Urol Oncol; 2015 Apr; 33(4):164.e1-9. PubMed ID: 25620154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncologic and Functional Outcomes after Radical Prostatectomy for High or Very High Risk Prostate Cancer: European Validation of the Current NCCN® Guideline.
    Pompe RS; Karakiewicz PI; Tian Z; Mandel P; Steuber T; Schlomm T; Salomon G; Graefen M; Huland H; Tilki D
    J Urol; 2017 Aug; 198(2):354-361. PubMed ID: 28216329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.